Steph & Co. Grows Stock Position in argenx SE (NASDAQ:ARGX)

Steph & Co. raised its holdings in shares of argenx SE (NASDAQ:ARGX) by 27.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 413 shares of the company’s stock after acquiring an additional 88 shares during the quarter. Steph & Co.’s holdings in argenx were worth $163,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the business. Wellington Management Group LLP grew its position in shares of argenx by 26.2% in the fourth quarter. Wellington Management Group LLP now owns 279,168 shares of the company’s stock valued at $106,204,000 after purchasing an additional 57,956 shares during the last quarter. Sectoral Asset Management Inc. grew its holdings in argenx by 717.2% during the 4th quarter. Sectoral Asset Management Inc. now owns 10,027 shares of the company’s stock valued at $3,815,000 after buying an additional 8,800 shares during the last quarter. Boxer Capital LLC increased its position in argenx by 88.2% during the fourth quarter. Boxer Capital LLC now owns 160,000 shares of the company’s stock worth $60,869,000 after buying an additional 75,000 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of argenx by 9.1% in the fourth quarter. The Manufacturers Life Insurance Company now owns 47,583 shares of the company’s stock worth $18,102,000 after acquiring an additional 3,967 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. raised its holdings in shares of argenx by 30.4% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 14,470 shares of the company’s stock worth $5,505,000 after acquiring an additional 3,374 shares during the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ARGX has been the subject of a number of recent research reports. Truist Financial lifted their price objective on argenx from $370.00 to $440.00 and gave the stock a “buy” rating in a research report on Tuesday, March 5th. Scotiabank lifted their price target on shares of argenx from $402.00 to $408.00 and gave the stock a “sector perform” rating in a report on Tuesday, March 26th. Morgan Stanley reduced their price objective on shares of argenx from $515.00 to $510.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 28th. HC Wainwright restated a “buy” rating and set a $448.00 target price on shares of argenx in a research report on Monday. Finally, Stifel Nicolaus boosted their price target on argenx from $485.00 to $500.00 and gave the company a “buy” rating in a report on Monday. Five research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $523.42.

argenx Stock Up 11.7 %

NASDAQ ARGX opened at $440.59 on Tuesday. argenx SE has a fifty-two week low of $327.73 and a fifty-two week high of $550.76. The stock has a market cap of $26.18 billion, a PE ratio of -77.84 and a beta of 0.65. The business has a 50 day moving average price of $376.64 and a two-hundred day moving average price of $386.49.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Monday, May 13th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.33). The firm had revenue of $412.51 million during the quarter, compared to the consensus estimate of $404.03 million. argenx had a negative net margin of 22.58% and a negative return on equity of 14.14%. During the same period in the prior year, the firm earned ($0.52) earnings per share. Sell-side analysts anticipate that argenx SE will post -2.75 EPS for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.